Outset Medical

Outset Medical, Inc. is a rapidly growing medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. Its Tablo® Hemodialysis System (Tablo) represents a significant technological advancement enabling novel, transformational dialysis care in acute and home settings. Tablo was designed from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone.
Outset Medical stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Outset Medical balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Outset Medical cash flows

Report period2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Outset Medical multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Outset Medical profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Outset Medical assets
Outset Medical cash flows

Outset Medical dividend policy

The company doesn't provide dividend.

Outset Medical shares

TickerNameTypeNominal valueISINPrice
OM:USOutset MedicalCommon share-US6901451079$0.7919
Outset Medical news
05.05.2022
Outset Medical's GAAP loss for 3 months of 2022 was $36.892 million, up 22.9% from $30.025 million in the prior year. Revenue increased 33.3% to $30.55 million from $22.916 million a year earlier.
17.02.2022
Outset Medical's GAAP loss for 2021 was $131.935 million, up 8.6% from $121.492 million in the prior year. Revenue increased 2.1 times to $102.602 million from $49.935 million a year earlier.
30.11.2021
Outset Medical has received FDA approval for a new method to sterilize the cartridge used in the Tablo hemodialysis system. This will allow the production of disposable cartridges to be ordered in Mexico, reducing the need for costly and limited-capacity air shipments of cartridges.
04.11.2021
Outset Medical reported a GAAP loss of $90.703 million for 9M 2021, up 1.4% from $89.449 million in the previous year. Revenues increased 2.3 times to $74.45 million from $32.688 million a year earlier.
General information
Company nameOutset Medical
SectorInformation Technology / Software & Services / Software / Application Software
Business address3052 Orchard Drive San Jose, CA 95134 United States
Websiteinvestors.outsetmedical.com
Information disclosurewww.sec.gov